nodes	percent_of_prediction	percent_of_DWPC	metapath
Lomefloxacin—TOP2A—Valrubicin—urinary bladder cancer	0.505	0.621	CbGbCtD
Lomefloxacin—TOP2A—Epirubicin—urinary bladder cancer	0.0765	0.0941	CbGbCtD
Lomefloxacin—TOP2A—Etoposide—urinary bladder cancer	0.0596	0.0733	CbGbCtD
Lomefloxacin—TOP2A—Doxorubicin—urinary bladder cancer	0.0407	0.05	CbGbCtD
Lomefloxacin—ABCC2—Carboplatin—urinary bladder cancer	0.0291	0.0358	CbGbCtD
Lomefloxacin—ABCC2—Cisplatin—urinary bladder cancer	0.0249	0.0306	CbGbCtD
Lomefloxacin—ABCC2—Etoposide—urinary bladder cancer	0.0245	0.0301	CbGbCtD
Lomefloxacin—ABCC2—Doxorubicin—urinary bladder cancer	0.0167	0.0205	CbGbCtD
Lomefloxacin—ABCC2—Methotrexate—urinary bladder cancer	0.0162	0.0199	CbGbCtD
Lomefloxacin—CYP1A2—Fluorouracil—urinary bladder cancer	0.0109	0.0134	CbGbCtD
Lomefloxacin—CYP1A2—Etoposide—urinary bladder cancer	0.00912	0.0112	CbGbCtD
Lomefloxacin—ABCC2—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00433	0.117	CbGpPWpGaD
Lomefloxacin—CYP1A2—urine—urinary bladder cancer	0.00179	0.175	CbGeAlD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.0015	0.0404	CbGpPWpGaD
Lomefloxacin—TOP2A—prostate gland—urinary bladder cancer	0.00134	0.131	CbGeAlD
Lomefloxacin—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00122	0.033	CbGpPWpGaD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00122	0.033	CbGpPWpGaD
Lomefloxacin—ABCC2—prostate gland—urinary bladder cancer	0.000913	0.0896	CbGeAlD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.000908	0.0244	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC14A2—urinary bladder cancer	0.000879	0.0237	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.000849	0.0229	CbGpPWpGaD
Lomefloxacin—TOP2A—G0 and Early G1—CCNE1—urinary bladder cancer	0.000757	0.0204	CbGpPWpGaD
Lomefloxacin—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00075	0.0202	CbGpPWpGaD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.000713	0.0192	CbGpPWpGaD
Lomefloxacin—SLC22A5—prostate gland—urinary bladder cancer	0.000707	0.0694	CbGeAlD
Lomefloxacin—TOP2A—vagina—urinary bladder cancer	0.00066	0.0647	CbGeAlD
Lomefloxacin—ABCC2—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000628	0.0169	CbGpPWpGaD
Lomefloxacin—ABCC2—renal system—urinary bladder cancer	0.000622	0.061	CbGeAlD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.000609	0.0164	CbGpPWpGaD
Lomefloxacin—SLC22A5—seminal vesicle—urinary bladder cancer	0.000598	0.0587	CbGeAlD
Lomefloxacin—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000542	0.125	CbGdCrCtD
Lomefloxacin—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000542	0.125	CbGdCrCtD
Lomefloxacin—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000542	0.125	CbGdCrCtD
Lomefloxacin—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000542	0.125	CbGdCrCtD
Lomefloxacin—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.000535	0.0144	CbGpPWpGaD
Lomefloxacin—ABCC2—female reproductive system—urinary bladder cancer	0.000498	0.0489	CbGeAlD
Lomefloxacin—SLC22A5—renal system—urinary bladder cancer	0.000482	0.0473	CbGeAlD
Lomefloxacin—SLC22A5—urethra—urinary bladder cancer	0.000474	0.0465	CbGeAlD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RRM2—urinary bladder cancer	0.000474	0.0128	CbGpPWpGaD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00046	0.0124	CbGpPWpGaD
Lomefloxacin—CYP1A2—renal system—urinary bladder cancer	0.000437	0.0428	CbGeAlD
Lomefloxacin—TOP2A—Circadian rythm related genes—KMT2A—urinary bladder cancer	0.000436	0.0117	CbGpPWpGaD
Lomefloxacin—TOP2A—lymph node—urinary bladder cancer	0.000427	0.0418	CbGeAlD
Lomefloxacin—ABCC2—NRF2 pathway—UGT2B7—urinary bladder cancer	0.000424	0.0114	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—SMC1A—urinary bladder cancer	0.000403	0.0108	CbGpPWpGaD
Lomefloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC14A2—urinary bladder cancer	0.000399	0.0108	CbGpPWpGaD
Lomefloxacin—SLC22A5—female reproductive system—urinary bladder cancer	0.000386	0.0379	CbGeAlD
Lomefloxacin—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000362	0.0835	CbGdCrCtD
Lomefloxacin—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000362	0.0835	CbGdCrCtD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.000351	0.00946	CbGpPWpGaD
Lomefloxacin—SLC22A5—vagina—urinary bladder cancer	0.000349	0.0343	CbGeAlD
Lomefloxacin—TOP2A—Cell Cycle—SMC1B—urinary bladder cancer	0.000342	0.00921	CbGpPWpGaD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.000338	0.00909	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—RRM2—urinary bladder cancer	0.000333	0.00897	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.000328	0.00883	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000307	0.00825	CbGpPWpGaD
Lomefloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000292	0.00786	CbGpPWpGaD
Lomefloxacin—ABCC2—lymph node—urinary bladder cancer	0.000292	0.0286	CbGeAlD
Lomefloxacin—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000288	0.00776	CbGpPWpGaD
Lomefloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000288	0.00775	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCNE1—urinary bladder cancer	0.000279	0.00752	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.000275	0.00741	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TYMS—urinary bladder cancer	0.000274	0.00738	CbGpPWpGaD
Lomefloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.000267	0.0072	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000261	0.00702	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000261	0.00702	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000256	0.00689	CbGpPWpGaD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—MYC—urinary bladder cancer	0.000253	0.00681	CbGpPWpGaD
Lomefloxacin—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000251	0.00676	CbGpPWpGaD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—EGFR—urinary bladder cancer	0.000247	0.00666	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.000239	0.00642	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000237	0.00637	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	0.000234	0.0063	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000232	0.00626	CbGpPWpGaD
Lomefloxacin—SLC22A5—lymph node—urinary bladder cancer	0.000226	0.0222	CbGeAlD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000214	0.00575	CbGpPWpGaD
Lomefloxacin—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	0.000208	0.00559	CbGpPWpGaD
Lomefloxacin—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	0.000203	0.047	CbGdCrCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000203	0.00547	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	0.000196	0.00529	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	0.000196	0.00527	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	0.000193	0.00519	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000192	0.00517	CbGpPWpGaD
Lomefloxacin—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Lomefloxacin—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Lomefloxacin—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	0.000189	0.0436	CbGdCrCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000187	0.00504	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	0.000186	0.005	CbGpPWpGaD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00018	0.00483	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	0.000175	0.00471	CbGpPWpGaD
Lomefloxacin—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Lomefloxacin—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Lomefloxacin—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	0.000175	0.0403	CbGdCrCtD
Lomefloxacin—ABCC2—NRF2 pathway—NQO1—urinary bladder cancer	0.000164	0.00441	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000161	0.00433	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000159	0.00427	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000155	0.00417	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000155	0.00417	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000153	0.00411	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000153	0.00411	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00015	0.00405	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.00015	0.00405	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000149	0.00401	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	0.000148	0.004	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.000148	0.004	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.000148	0.004	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000147	0.00395	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000146	0.00393	CbGpPWpGaD
Lomefloxacin—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	0.000146	0.0337	CbGdCrCtD
Lomefloxacin—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000143	0.00385	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.00014	0.00378	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.00014	0.00376	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000139	0.00373	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000138	0.00372	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000138	0.00371	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—GSTP1—urinary bladder cancer	0.000136	0.00367	CbGpPWpGaD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.000134	0.0036	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	0.000133	0.00357	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	0.000133	0.00357	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000131	0.00352	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000129	0.00349	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000126	0.00338	CbGpPWpGaD
Lomefloxacin—ABCC2—NRF2 pathway—GSTM1—urinary bladder cancer	0.000125	0.00338	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000124	0.00335	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000124	0.00334	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	0.000122	0.00329	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	0.00012	0.00322	CbGpPWpGaD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	0.000115	0.0031	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000114	0.00308	CbGpPWpGaD
Lomefloxacin—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000114	0.00308	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000114	0.00307	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000113	0.00306	CbGpPWpGaD
Lomefloxacin—Hyperglycaemia—Epirubicin—urinary bladder cancer	0.000113	0.000838	CcSEcCtD
Lomefloxacin—Somnolence—Etoposide—urinary bladder cancer	0.000113	0.000838	CcSEcCtD
Lomefloxacin—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000113	0.000838	CcSEcCtD
Lomefloxacin—Epistaxis—Methotrexate—urinary bladder cancer	0.000113	0.000835	CcSEcCtD
Lomefloxacin—Vomiting—Thiotepa—urinary bladder cancer	0.000113	0.000835	CcSEcCtD
Lomefloxacin—Rash—Thiotepa—urinary bladder cancer	0.000112	0.000828	CcSEcCtD
Lomefloxacin—Dermatitis—Thiotepa—urinary bladder cancer	0.000112	0.000827	CcSEcCtD
Lomefloxacin—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000112	0.000826	CcSEcCtD
Lomefloxacin—Headache—Thiotepa—urinary bladder cancer	0.000111	0.000822	CcSEcCtD
Lomefloxacin—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000111	0.000822	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000111	0.00298	CbGpPWpGaD
Lomefloxacin—Decreased appetite—Etoposide—urinary bladder cancer	0.000111	0.00082	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	0.000111	0.00298	CbGpPWpGaD
Lomefloxacin—Renal failure—Epirubicin—urinary bladder cancer	0.00011	0.000815	CcSEcCtD
Lomefloxacin—Fatigue—Etoposide—urinary bladder cancer	0.00011	0.000813	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.00011	0.000812	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000109	0.00295	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	0.000109	0.00294	CbGpPWpGaD
Lomefloxacin—Stomatitis—Epirubicin—urinary bladder cancer	0.000109	0.000808	CcSEcCtD
Lomefloxacin—Constipation—Etoposide—urinary bladder cancer	0.000109	0.000806	CcSEcCtD
Lomefloxacin—Conjunctivitis—Epirubicin—urinary bladder cancer	0.000109	0.000806	CcSEcCtD
Lomefloxacin—Dysuria—Doxorubicin—urinary bladder cancer	0.000109	0.000804	CcSEcCtD
Lomefloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000108	0.00291	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000108	0.0008	CcSEcCtD
Lomefloxacin—Hepatitis—Methotrexate—urinary bladder cancer	0.000107	0.000795	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	0.000107	0.00289	CbGpPWpGaD
Lomefloxacin—Asthenia—Gemcitabine—urinary bladder cancer	0.000107	0.000792	CcSEcCtD
Lomefloxacin—Haematuria—Epirubicin—urinary bladder cancer	0.000107	0.00079	CcSEcCtD
Lomefloxacin—Pharyngitis—Methotrexate—urinary bladder cancer	0.000107	0.000789	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000106	0.00286	CbGpPWpGaD
Lomefloxacin—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000106	0.000785	CcSEcCtD
Lomefloxacin—Epistaxis—Epirubicin—urinary bladder cancer	0.000106	0.000782	CcSEcCtD
Lomefloxacin—Pruritus—Gemcitabine—urinary bladder cancer	0.000106	0.000781	CcSEcCtD
Lomefloxacin—Nausea—Thiotepa—urinary bladder cancer	0.000105	0.00078	CcSEcCtD
Lomefloxacin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000105	0.000777	CcSEcCtD
Lomefloxacin—Hyperglycaemia—Doxorubicin—urinary bladder cancer	0.000105	0.000776	CcSEcCtD
Lomefloxacin—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000104	0.000773	CcSEcCtD
Lomefloxacin—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000104	0.000771	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	0.000104	0.0028	CbGpPWpGaD
Lomefloxacin—Pruritus—Fluorouracil—urinary bladder cancer	0.000104	0.000768	CcSEcCtD
Lomefloxacin—Visual impairment—Methotrexate—urinary bladder cancer	0.000103	0.000766	CcSEcCtD
Lomefloxacin—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000103	0.00076	CcSEcCtD
Lomefloxacin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000102	0.000758	CcSEcCtD
Lomefloxacin—Bradycardia—Epirubicin—urinary bladder cancer	0.000102	0.000757	CcSEcCtD
Lomefloxacin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000102	0.000756	CcSEcCtD
Lomefloxacin—Renal failure—Doxorubicin—urinary bladder cancer	0.000102	0.000754	CcSEcCtD
Lomefloxacin—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000102	0.000752	CcSEcCtD
Lomefloxacin—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000102	0.000752	CcSEcCtD
Lomefloxacin—Urticaria—Etoposide—urinary bladder cancer	0.000101	0.000749	CcSEcCtD
Lomefloxacin—Stomatitis—Doxorubicin—urinary bladder cancer	0.000101	0.000747	CcSEcCtD
Lomefloxacin—Rhinitis—Epirubicin—urinary bladder cancer	0.000101	0.000746	CcSEcCtD
Lomefloxacin—Abdominal pain—Etoposide—urinary bladder cancer	0.000101	0.000745	CcSEcCtD
Lomefloxacin—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000101	0.000745	CcSEcCtD
Lomefloxacin—Hepatitis—Epirubicin—urinary bladder cancer	0.0001	0.000744	CcSEcCtD
Lomefloxacin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.0001	0.000743	CcSEcCtD
Lomefloxacin—Tinnitus—Methotrexate—urinary bladder cancer	0.0001	0.000741	CcSEcCtD
Lomefloxacin—Asthenia—Cisplatin—urinary bladder cancer	9.98e-05	0.000738	CcSEcCtD
Lomefloxacin—Pharyngitis—Epirubicin—urinary bladder cancer	9.97e-05	0.000738	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	9.94e-05	0.00268	CbGpPWpGaD
Lomefloxacin—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	9.94e-05	0.00268	CbGpPWpGaD
Lomefloxacin—Haematuria—Doxorubicin—urinary bladder cancer	9.88e-05	0.000731	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	9.82e-05	0.00264	CbGpPWpGaD
Lomefloxacin—Epistaxis—Doxorubicin—urinary bladder cancer	9.77e-05	0.000723	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	9.71e-05	0.00261	CbGpPWpGaD
Lomefloxacin—Dizziness—Fluorouracil—urinary bladder cancer	9.7e-05	0.000718	CcSEcCtD
Lomefloxacin—Visual impairment—Epirubicin—urinary bladder cancer	9.69e-05	0.000717	CcSEcCtD
Lomefloxacin—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.67e-05	0.000716	CcSEcCtD
Lomefloxacin—Chills—Methotrexate—urinary bladder cancer	9.64e-05	0.000713	CcSEcCtD
Lomefloxacin—Diarrhoea—Cisplatin—urinary bladder cancer	9.51e-05	0.000704	CcSEcCtD
Lomefloxacin—Erythema multiforme—Epirubicin—urinary bladder cancer	9.5e-05	0.000703	CcSEcCtD
Lomefloxacin—Vomiting—Gemcitabine—urinary bladder cancer	9.48e-05	0.000702	CcSEcCtD
Lomefloxacin—Bradycardia—Doxorubicin—urinary bladder cancer	9.47e-05	0.000701	CcSEcCtD
Lomefloxacin—Rash—Gemcitabine—urinary bladder cancer	9.41e-05	0.000696	CcSEcCtD
Lomefloxacin—Dermatitis—Gemcitabine—urinary bladder cancer	9.4e-05	0.000696	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	9.39e-05	0.00253	CbGpPWpGaD
Lomefloxacin—Hypersensitivity—Etoposide—urinary bladder cancer	9.38e-05	0.000695	CcSEcCtD
Lomefloxacin—Tinnitus—Epirubicin—urinary bladder cancer	9.37e-05	0.000694	CcSEcCtD
Lomefloxacin—Headache—Gemcitabine—urinary bladder cancer	9.34e-05	0.000692	CcSEcCtD
Lomefloxacin—Flushing—Epirubicin—urinary bladder cancer	9.33e-05	0.00069	CcSEcCtD
Lomefloxacin—Vomiting—Fluorouracil—urinary bladder cancer	9.33e-05	0.00069	CcSEcCtD
Lomefloxacin—Rhinitis—Doxorubicin—urinary bladder cancer	9.32e-05	0.00069	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	9.31e-05	0.00251	CbGpPWpGaD
Lomefloxacin—Hepatitis—Doxorubicin—urinary bladder cancer	9.3e-05	0.000688	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	9.29e-05	0.0025	CbGpPWpGaD
Lomefloxacin—Rash—Fluorouracil—urinary bladder cancer	9.25e-05	0.000685	CcSEcCtD
Lomefloxacin—Dermatitis—Fluorouracil—urinary bladder cancer	9.24e-05	0.000684	CcSEcCtD
Lomefloxacin—Pharyngitis—Doxorubicin—urinary bladder cancer	9.23e-05	0.000683	CcSEcCtD
Lomefloxacin—Headache—Fluorouracil—urinary bladder cancer	9.19e-05	0.00068	CcSEcCtD
Lomefloxacin—Dysgeusia—Methotrexate—urinary bladder cancer	9.15e-05	0.000678	CcSEcCtD
Lomefloxacin—Asthenia—Etoposide—urinary bladder cancer	9.14e-05	0.000677	CcSEcCtD
Lomefloxacin—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	9.09e-05	0.00245	CbGpPWpGaD
Lomefloxacin—Back pain—Methotrexate—urinary bladder cancer	9.04e-05	0.000669	CcSEcCtD
Lomefloxacin—Chills—Epirubicin—urinary bladder cancer	9.02e-05	0.000668	CcSEcCtD
Lomefloxacin—Pruritus—Etoposide—urinary bladder cancer	9.01e-05	0.000667	CcSEcCtD
Lomefloxacin—Arrhythmia—Epirubicin—urinary bladder cancer	8.98e-05	0.000665	CcSEcCtD
Lomefloxacin—Visual impairment—Doxorubicin—urinary bladder cancer	8.96e-05	0.000663	CcSEcCtD
Lomefloxacin—Nausea—Gemcitabine—urinary bladder cancer	8.86e-05	0.000656	CcSEcCtD
Lomefloxacin—Vomiting—Cisplatin—urinary bladder cancer	8.84e-05	0.000654	CcSEcCtD
Lomefloxacin—Erythema multiforme—Doxorubicin—urinary bladder cancer	8.79e-05	0.000651	CcSEcCtD
Lomefloxacin—Rash—Cisplatin—urinary bladder cancer	8.77e-05	0.000649	CcSEcCtD
Lomefloxacin—Dermatitis—Cisplatin—urinary bladder cancer	8.76e-05	0.000648	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.75e-05	0.00236	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Etoposide—urinary bladder cancer	8.72e-05	0.000645	CcSEcCtD
Lomefloxacin—Nausea—Fluorouracil—urinary bladder cancer	8.71e-05	0.000645	CcSEcCtD
Lomefloxacin—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.67e-05	0.000642	CcSEcCtD
Lomefloxacin—Tinnitus—Doxorubicin—urinary bladder cancer	8.67e-05	0.000642	CcSEcCtD
Lomefloxacin—Anaemia—Methotrexate—urinary bladder cancer	8.64e-05	0.00064	CcSEcCtD
Lomefloxacin—Flushing—Doxorubicin—urinary bladder cancer	8.63e-05	0.000639	CcSEcCtD
Lomefloxacin—Flatulence—Epirubicin—urinary bladder cancer	8.62e-05	0.000638	CcSEcCtD
Lomefloxacin—Tension—Epirubicin—urinary bladder cancer	8.59e-05	0.000636	CcSEcCtD
Lomefloxacin—Dysgeusia—Epirubicin—urinary bladder cancer	8.57e-05	0.000634	CcSEcCtD
Lomefloxacin—Nervousness—Epirubicin—urinary bladder cancer	8.5e-05	0.000629	CcSEcCtD
Lomefloxacin—Back pain—Epirubicin—urinary bladder cancer	8.46e-05	0.000626	CcSEcCtD
Lomefloxacin—Malaise—Methotrexate—urinary bladder cancer	8.43e-05	0.000624	CcSEcCtD
Lomefloxacin—Dizziness—Etoposide—urinary bladder cancer	8.42e-05	0.000624	CcSEcCtD
Lomefloxacin—Muscle spasms—Epirubicin—urinary bladder cancer	8.41e-05	0.000623	CcSEcCtD
Lomefloxacin—Vertigo—Methotrexate—urinary bladder cancer	8.4e-05	0.000622	CcSEcCtD
Lomefloxacin—Leukopenia—Methotrexate—urinary bladder cancer	8.37e-05	0.000619	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	8.36e-05	0.00225	CbGpPWpGaD
Lomefloxacin—Chills—Doxorubicin—urinary bladder cancer	8.34e-05	0.000618	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.33e-05	0.00224	CbGpPWpGaD
Lomefloxacin—Arrhythmia—Doxorubicin—urinary bladder cancer	8.31e-05	0.000615	CcSEcCtD
Lomefloxacin—Nausea—Cisplatin—urinary bladder cancer	8.26e-05	0.000611	CcSEcCtD
Lomefloxacin—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	8.24e-05	0.00222	CbGpPWpGaD
Lomefloxacin—Cough—Methotrexate—urinary bladder cancer	8.16e-05	0.000604	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.14e-05	0.00219	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	8.13e-05	0.00219	CbGpPWpGaD
Lomefloxacin—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.12e-05	0.000601	CcSEcCtD
Lomefloxacin—Convulsion—Methotrexate—urinary bladder cancer	8.1e-05	0.0006	CcSEcCtD
Lomefloxacin—Vomiting—Etoposide—urinary bladder cancer	8.1e-05	0.0006	CcSEcCtD
Lomefloxacin—Anaemia—Epirubicin—urinary bladder cancer	8.09e-05	0.000599	CcSEcCtD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.08e-05	0.00218	CbGpPWpGaD
Lomefloxacin—Agitation—Epirubicin—urinary bladder cancer	8.04e-05	0.000595	CcSEcCtD
Lomefloxacin—Rash—Etoposide—urinary bladder cancer	8.03e-05	0.000595	CcSEcCtD
Lomefloxacin—Dermatitis—Etoposide—urinary bladder cancer	8.02e-05	0.000594	CcSEcCtD
Lomefloxacin—Headache—Etoposide—urinary bladder cancer	7.98e-05	0.000591	CcSEcCtD
Lomefloxacin—Flatulence—Doxorubicin—urinary bladder cancer	7.98e-05	0.00059	CcSEcCtD
Lomefloxacin—Myalgia—Methotrexate—urinary bladder cancer	7.96e-05	0.000589	CcSEcCtD
Lomefloxacin—Chest pain—Methotrexate—urinary bladder cancer	7.96e-05	0.000589	CcSEcCtD
Lomefloxacin—Arthralgia—Methotrexate—urinary bladder cancer	7.96e-05	0.000589	CcSEcCtD
Lomefloxacin—Tension—Doxorubicin—urinary bladder cancer	7.94e-05	0.000588	CcSEcCtD
Lomefloxacin—Dysgeusia—Doxorubicin—urinary bladder cancer	7.93e-05	0.000587	CcSEcCtD
Lomefloxacin—Malaise—Epirubicin—urinary bladder cancer	7.89e-05	0.000584	CcSEcCtD
Lomefloxacin—Discomfort—Methotrexate—urinary bladder cancer	7.86e-05	0.000582	CcSEcCtD
Lomefloxacin—Nervousness—Doxorubicin—urinary bladder cancer	7.86e-05	0.000582	CcSEcCtD
Lomefloxacin—Vertigo—Epirubicin—urinary bladder cancer	7.86e-05	0.000582	CcSEcCtD
Lomefloxacin—Syncope—Epirubicin—urinary bladder cancer	7.85e-05	0.000581	CcSEcCtD
Lomefloxacin—Leukopenia—Epirubicin—urinary bladder cancer	7.83e-05	0.00058	CcSEcCtD
Lomefloxacin—Back pain—Doxorubicin—urinary bladder cancer	7.83e-05	0.00058	CcSEcCtD
Lomefloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	7.79e-05	0.0021	CbGpPWpGaD
Lomefloxacin—Muscle spasms—Doxorubicin—urinary bladder cancer	7.78e-05	0.000576	CcSEcCtD
Lomefloxacin—Confusional state—Methotrexate—urinary bladder cancer	7.69e-05	0.000569	CcSEcCtD
Lomefloxacin—Loss of consciousness—Epirubicin—urinary bladder cancer	7.69e-05	0.000569	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	7.68e-05	0.00207	CbGpPWpGaD
Lomefloxacin—Cough—Epirubicin—urinary bladder cancer	7.63e-05	0.000565	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.63e-05	0.000565	CcSEcCtD
Lomefloxacin—Convulsion—Epirubicin—urinary bladder cancer	7.58e-05	0.000561	CcSEcCtD
Lomefloxacin—Nausea—Etoposide—urinary bladder cancer	7.57e-05	0.00056	CcSEcCtD
Lomefloxacin—Hypertension—Epirubicin—urinary bladder cancer	7.55e-05	0.000559	CcSEcCtD
Lomefloxacin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.51e-05	0.000556	CcSEcCtD
Lomefloxacin—Anaemia—Doxorubicin—urinary bladder cancer	7.48e-05	0.000554	CcSEcCtD
Lomefloxacin—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.47e-05	0.000553	CcSEcCtD
Lomefloxacin—Chest pain—Epirubicin—urinary bladder cancer	7.45e-05	0.000551	CcSEcCtD
Lomefloxacin—Myalgia—Epirubicin—urinary bladder cancer	7.45e-05	0.000551	CcSEcCtD
Lomefloxacin—Arthralgia—Epirubicin—urinary bladder cancer	7.45e-05	0.000551	CcSEcCtD
Lomefloxacin—Agitation—Doxorubicin—urinary bladder cancer	7.44e-05	0.000551	CcSEcCtD
Lomefloxacin—Anxiety—Epirubicin—urinary bladder cancer	7.42e-05	0.000549	CcSEcCtD
Lomefloxacin—Skin disorder—Methotrexate—urinary bladder cancer	7.41e-05	0.000549	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Methotrexate—urinary bladder cancer	7.38e-05	0.000546	CcSEcCtD
Lomefloxacin—Discomfort—Epirubicin—urinary bladder cancer	7.36e-05	0.000545	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.36e-05	0.00198	CbGpPWpGaD
Lomefloxacin—Malaise—Doxorubicin—urinary bladder cancer	7.3e-05	0.00054	CcSEcCtD
Lomefloxacin—Dry mouth—Epirubicin—urinary bladder cancer	7.28e-05	0.000539	CcSEcCtD
Lomefloxacin—Vertigo—Doxorubicin—urinary bladder cancer	7.27e-05	0.000538	CcSEcCtD
Lomefloxacin—Anorexia—Methotrexate—urinary bladder cancer	7.27e-05	0.000538	CcSEcCtD
Lomefloxacin—Syncope—Doxorubicin—urinary bladder cancer	7.26e-05	0.000537	CcSEcCtD
Lomefloxacin—Leukopenia—Doxorubicin—urinary bladder cancer	7.25e-05	0.000536	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	7.2e-05	0.00194	CbGpPWpGaD
Lomefloxacin—Confusional state—Epirubicin—urinary bladder cancer	7.2e-05	0.000533	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.14e-05	0.000529	CcSEcCtD
Lomefloxacin—Oedema—Epirubicin—urinary bladder cancer	7.14e-05	0.000529	CcSEcCtD
Lomefloxacin—Hypotension—Methotrexate—urinary bladder cancer	7.13e-05	0.000528	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.12e-05	0.00192	CbGpPWpGaD
Lomefloxacin—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.11e-05	0.000527	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.1e-05	0.00191	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	7.07e-05	0.0019	CbGpPWpGaD
Lomefloxacin—Cough—Doxorubicin—urinary bladder cancer	7.06e-05	0.000523	CcSEcCtD
Lomefloxacin—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	7.06e-05	0.0019	CbGpPWpGaD
Lomefloxacin—Shock—Epirubicin—urinary bladder cancer	7.02e-05	0.00052	CcSEcCtD
Lomefloxacin—Convulsion—Doxorubicin—urinary bladder cancer	7.01e-05	0.000519	CcSEcCtD
Lomefloxacin—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.99e-05	0.000518	CcSEcCtD
Lomefloxacin—Hypertension—Doxorubicin—urinary bladder cancer	6.99e-05	0.000517	CcSEcCtD
Lomefloxacin—Tachycardia—Epirubicin—urinary bladder cancer	6.97e-05	0.000516	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.95e-05	0.000515	CcSEcCtD
Lomefloxacin—Skin disorder—Epirubicin—urinary bladder cancer	6.94e-05	0.000513	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.9e-05	0.000511	CcSEcCtD
Lomefloxacin—Insomnia—Methotrexate—urinary bladder cancer	6.9e-05	0.000511	CcSEcCtD
Lomefloxacin—Arthralgia—Doxorubicin—urinary bladder cancer	6.89e-05	0.00051	CcSEcCtD
Lomefloxacin—Chest pain—Doxorubicin—urinary bladder cancer	6.89e-05	0.00051	CcSEcCtD
Lomefloxacin—Myalgia—Doxorubicin—urinary bladder cancer	6.89e-05	0.00051	CcSEcCtD
Lomefloxacin—Anxiety—Doxorubicin—urinary bladder cancer	6.87e-05	0.000508	CcSEcCtD
Lomefloxacin—Paraesthesia—Methotrexate—urinary bladder cancer	6.85e-05	0.000507	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	6.82e-05	0.00184	CbGpPWpGaD
Lomefloxacin—Discomfort—Doxorubicin—urinary bladder cancer	6.81e-05	0.000504	CcSEcCtD
Lomefloxacin—Anorexia—Epirubicin—urinary bladder cancer	6.81e-05	0.000504	CcSEcCtD
Lomefloxacin—Dyspnoea—Methotrexate—urinary bladder cancer	6.8e-05	0.000504	CcSEcCtD
Lomefloxacin—Somnolence—Methotrexate—urinary bladder cancer	6.78e-05	0.000502	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	6.77e-05	0.00182	CbGpPWpGaD
Lomefloxacin—Dry mouth—Doxorubicin—urinary bladder cancer	6.74e-05	0.000499	CcSEcCtD
Lomefloxacin—Dyspepsia—Methotrexate—urinary bladder cancer	6.72e-05	0.000497	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	6.68e-05	0.0018	CbGpPWpGaD
Lomefloxacin—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	6.68e-05	0.0018	CbGpPWpGaD
Lomefloxacin—Hypotension—Epirubicin—urinary bladder cancer	6.67e-05	0.000494	CcSEcCtD
Lomefloxacin—Confusional state—Doxorubicin—urinary bladder cancer	6.66e-05	0.000493	CcSEcCtD
Lomefloxacin—Decreased appetite—Methotrexate—urinary bladder cancer	6.63e-05	0.000491	CcSEcCtD
Lomefloxacin—Oedema—Doxorubicin—urinary bladder cancer	6.61e-05	0.000489	CcSEcCtD
Lomefloxacin—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.61e-05	0.000489	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.59e-05	0.00177	CbGpPWpGaD
Lomefloxacin—Fatigue—Methotrexate—urinary bladder cancer	6.58e-05	0.000487	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.51e-05	0.000482	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	6.5e-05	0.00175	CbGpPWpGaD
Lomefloxacin—Shock—Doxorubicin—urinary bladder cancer	6.5e-05	0.000481	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	6.48e-05	0.00175	CbGpPWpGaD
Lomefloxacin—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.47e-05	0.000479	CcSEcCtD
Lomefloxacin—Insomnia—Epirubicin—urinary bladder cancer	6.46e-05	0.000478	CcSEcCtD
Lomefloxacin—Tachycardia—Doxorubicin—urinary bladder cancer	6.45e-05	0.000477	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	6.44e-05	0.00173	CbGpPWpGaD
Lomefloxacin—Skin disorder—Doxorubicin—urinary bladder cancer	6.42e-05	0.000475	CcSEcCtD
Lomefloxacin—Paraesthesia—Epirubicin—urinary bladder cancer	6.41e-05	0.000475	CcSEcCtD
Lomefloxacin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	6.39e-05	0.000473	CcSEcCtD
Lomefloxacin—Dyspnoea—Epirubicin—urinary bladder cancer	6.37e-05	0.000471	CcSEcCtD
Lomefloxacin—Somnolence—Epirubicin—urinary bladder cancer	6.35e-05	0.00047	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	6.32e-05	0.0017	CbGpPWpGaD
Lomefloxacin—Anorexia—Doxorubicin—urinary bladder cancer	6.3e-05	0.000466	CcSEcCtD
Lomefloxacin—Feeling abnormal—Methotrexate—urinary bladder cancer	6.29e-05	0.000465	CcSEcCtD
Lomefloxacin—Dyspepsia—Epirubicin—urinary bladder cancer	6.29e-05	0.000465	CcSEcCtD
Lomefloxacin—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	6.25e-05	0.00168	CbGpPWpGaD
Lomefloxacin—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.24e-05	0.000462	CcSEcCtD
Lomefloxacin—Decreased appetite—Epirubicin—urinary bladder cancer	6.21e-05	0.000459	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	6.2e-05	0.00167	CbGpPWpGaD
Lomefloxacin—Hypotension—Doxorubicin—urinary bladder cancer	6.17e-05	0.000457	CcSEcCtD
Lomefloxacin—Fatigue—Epirubicin—urinary bladder cancer	6.16e-05	0.000456	CcSEcCtD
Lomefloxacin—Constipation—Epirubicin—urinary bladder cancer	6.11e-05	0.000452	CcSEcCtD
Lomefloxacin—Urticaria—Methotrexate—urinary bladder cancer	6.06e-05	0.000449	CcSEcCtD
Lomefloxacin—Abdominal pain—Methotrexate—urinary bladder cancer	6.03e-05	0.000446	CcSEcCtD
Lomefloxacin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.02e-05	0.000446	CcSEcCtD
Lomefloxacin—Insomnia—Doxorubicin—urinary bladder cancer	5.98e-05	0.000442	CcSEcCtD
Lomefloxacin—Paraesthesia—Doxorubicin—urinary bladder cancer	5.93e-05	0.000439	CcSEcCtD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.91e-05	0.00159	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	5.9e-05	0.00159	CbGpPWpGaD
Lomefloxacin—Dyspnoea—Doxorubicin—urinary bladder cancer	5.89e-05	0.000436	CcSEcCtD
Lomefloxacin—Feeling abnormal—Epirubicin—urinary bladder cancer	5.88e-05	0.000436	CcSEcCtD
Lomefloxacin—Somnolence—Doxorubicin—urinary bladder cancer	5.87e-05	0.000435	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	5.84e-05	0.00157	CbGpPWpGaD
Lomefloxacin—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.84e-05	0.000432	CcSEcCtD
Lomefloxacin—Dyspepsia—Doxorubicin—urinary bladder cancer	5.82e-05	0.00043	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	5.77e-05	0.00155	CbGpPWpGaD
Lomefloxacin—Decreased appetite—Doxorubicin—urinary bladder cancer	5.74e-05	0.000425	CcSEcCtD
Lomefloxacin—Fatigue—Doxorubicin—urinary bladder cancer	5.7e-05	0.000422	CcSEcCtD
Lomefloxacin—Urticaria—Epirubicin—urinary bladder cancer	5.67e-05	0.00042	CcSEcCtD
Lomefloxacin—Constipation—Doxorubicin—urinary bladder cancer	5.65e-05	0.000418	CcSEcCtD
Lomefloxacin—Abdominal pain—Epirubicin—urinary bladder cancer	5.64e-05	0.000418	CcSEcCtD
Lomefloxacin—Hypersensitivity—Methotrexate—urinary bladder cancer	5.62e-05	0.000416	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	5.56e-05	0.0015	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	5.56e-05	0.0015	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	5.52e-05	0.00149	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—TERT—urinary bladder cancer	5.51e-05	0.00148	CbGpPWpGaD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.5e-05	0.00148	CbGpPWpGaD
Lomefloxacin—Asthenia—Methotrexate—urinary bladder cancer	5.47e-05	0.000405	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.45e-05	0.00147	CbGpPWpGaD
Lomefloxacin—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.44e-05	0.000403	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	5.41e-05	0.00146	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	5.41e-05	0.00146	CbGpPWpGaD
Lomefloxacin—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.4e-05	0.0004	CcSEcCtD
Lomefloxacin—Pruritus—Methotrexate—urinary bladder cancer	5.4e-05	0.0004	CcSEcCtD
Lomefloxacin—Hypersensitivity—Epirubicin—urinary bladder cancer	5.26e-05	0.000389	CcSEcCtD
Lomefloxacin—Urticaria—Doxorubicin—urinary bladder cancer	5.25e-05	0.000389	CcSEcCtD
Lomefloxacin—Abdominal pain—Doxorubicin—urinary bladder cancer	5.22e-05	0.000387	CcSEcCtD
Lomefloxacin—Diarrhoea—Methotrexate—urinary bladder cancer	5.22e-05	0.000386	CcSEcCtD
Lomefloxacin—Asthenia—Epirubicin—urinary bladder cancer	5.12e-05	0.000379	CcSEcCtD
Lomefloxacin—Pruritus—Epirubicin—urinary bladder cancer	5.05e-05	0.000374	CcSEcCtD
Lomefloxacin—Dizziness—Methotrexate—urinary bladder cancer	5.05e-05	0.000373	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—ATM—urinary bladder cancer	4.95e-05	0.00133	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	4.93e-05	0.00133	CbGpPWpGaD
Lomefloxacin—Diarrhoea—Epirubicin—urinary bladder cancer	4.89e-05	0.000362	CcSEcCtD
Lomefloxacin—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.87e-05	0.00036	CcSEcCtD
Lomefloxacin—Vomiting—Methotrexate—urinary bladder cancer	4.85e-05	0.000359	CcSEcCtD
Lomefloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	4.85e-05	0.0013	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	4.84e-05	0.0013	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	4.82e-05	0.0013	CbGpPWpGaD
Lomefloxacin—Rash—Methotrexate—urinary bladder cancer	4.81e-05	0.000356	CcSEcCtD
Lomefloxacin—Dermatitis—Methotrexate—urinary bladder cancer	4.81e-05	0.000356	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	4.8e-05	0.00129	CbGpPWpGaD
Lomefloxacin—Headache—Methotrexate—urinary bladder cancer	4.78e-05	0.000354	CcSEcCtD
Lomefloxacin—Asthenia—Doxorubicin—urinary bladder cancer	4.74e-05	0.000351	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	4.74e-05	0.00128	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	4.74e-05	0.00128	CbGpPWpGaD
Lomefloxacin—Dizziness—Epirubicin—urinary bladder cancer	4.72e-05	0.00035	CcSEcCtD
Lomefloxacin—Pruritus—Doxorubicin—urinary bladder cancer	4.67e-05	0.000346	CcSEcCtD
Lomefloxacin—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	4.65e-05	0.00125	CbGpPWpGaD
Lomefloxacin—Vomiting—Epirubicin—urinary bladder cancer	4.54e-05	0.000336	CcSEcCtD
Lomefloxacin—Nausea—Methotrexate—urinary bladder cancer	4.53e-05	0.000335	CcSEcCtD
Lomefloxacin—Diarrhoea—Doxorubicin—urinary bladder cancer	4.52e-05	0.000335	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	4.51e-05	0.00122	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	4.51e-05	0.00122	CbGpPWpGaD
Lomefloxacin—Rash—Epirubicin—urinary bladder cancer	4.5e-05	0.000333	CcSEcCtD
Lomefloxacin—Dermatitis—Epirubicin—urinary bladder cancer	4.5e-05	0.000333	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	4.49e-05	0.00121	CbGpPWpGaD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	4.48e-05	0.00121	CbGpPWpGaD
Lomefloxacin—Headache—Epirubicin—urinary bladder cancer	4.47e-05	0.000331	CcSEcCtD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	4.43e-05	0.00119	CbGpPWpGaD
Lomefloxacin—Dizziness—Doxorubicin—urinary bladder cancer	4.37e-05	0.000323	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle—RB1—urinary bladder cancer	4.29e-05	0.00115	CbGpPWpGaD
Lomefloxacin—Nausea—Epirubicin—urinary bladder cancer	4.24e-05	0.000314	CcSEcCtD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	4.22e-05	0.00114	CbGpPWpGaD
Lomefloxacin—Vomiting—Doxorubicin—urinary bladder cancer	4.2e-05	0.000311	CcSEcCtD
Lomefloxacin—Rash—Doxorubicin—urinary bladder cancer	4.17e-05	0.000308	CcSEcCtD
Lomefloxacin—Dermatitis—Doxorubicin—urinary bladder cancer	4.16e-05	0.000308	CcSEcCtD
Lomefloxacin—Headache—Doxorubicin—urinary bladder cancer	4.14e-05	0.000306	CcSEcCtD
Lomefloxacin—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	4.13e-05	0.00111	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	4.07e-05	0.0011	CbGpPWpGaD
Lomefloxacin—Nausea—Doxorubicin—urinary bladder cancer	3.92e-05	0.00029	CcSEcCtD
Lomefloxacin—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	3.81e-05	0.00102	CbGpPWpGaD
Lomefloxacin—SLC22A5—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	3.78e-05	0.00102	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	3.77e-05	0.00101	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	3.56e-05	0.000959	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	3.45e-05	0.000928	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	3.28e-05	0.000883	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	3.18e-05	0.000858	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	3.08e-05	0.00083	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—EP300—urinary bladder cancer	2.93e-05	0.000789	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.86e-05	0.000769	CbGpPWpGaD
Lomefloxacin—ABCC2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.76e-05	0.000745	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	2.75e-05	0.000741	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	2.61e-05	0.000703	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NAT1—urinary bladder cancer	2.61e-05	0.000703	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.57e-05	0.000691	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.55e-05	0.000688	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	2.39e-05	0.000643	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	2.15e-05	0.000579	CbGpPWpGaD
Lomefloxacin—TOP2A—Cell Cycle—TP53—urinary bladder cancer	2.1e-05	0.000565	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	2.03e-05	0.000546	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	1.98e-05	0.000532	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.59e-05	0.000427	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—TYMP—urinary bladder cancer	1.58e-05	0.000426	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.52e-05	0.000409	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NAT2—urinary bladder cancer	1.43e-05	0.000385	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—RRM2—urinary bladder cancer	1.23e-05	0.000332	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ENO2—urinary bladder cancer	1.14e-05	0.000308	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	1.14e-05	0.000308	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.14e-05	0.000306	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	1.11e-05	0.000298	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.09e-05	0.000294	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NQO1—urinary bladder cancer	9.21e-06	0.000248	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.94e-06	0.000241	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.79e-06	0.00021	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	7.68e-06	0.000207	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.43e-06	0.0002	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—TYMS—urinary bladder cancer	7.14e-06	0.000192	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	7.06e-06	0.00019	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	7.06e-06	0.00019	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—GPX1—urinary bladder cancer	6.76e-06	0.000182	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	6.64e-06	0.000179	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	6.24e-06	0.000168	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PPARG—urinary bladder cancer	5.06e-06	0.000136	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	4.86e-06	0.000131	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	3.98e-06	0.000107	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—PTEN—urinary bladder cancer	3.47e-06	9.35e-05	CbGpPWpGaD
Lomefloxacin—CYP1A2—Metabolism—EP300—urinary bladder cancer	3.31e-06	8.91e-05	CbGpPWpGaD
